IDH1 and astrocytoma (excluding glioblastoma): Further, the study by Touat et al., 2020 which studied the mutational burden by profiling 10,294 gliomas, found that hypermutant tumors or tumors with high mutation burden have a worse overall survival as compared to non-hypermutant tumors in different types of glioma including 1p/19q co-deleted oligodendrogliomas, isocitrate dehydrogenase 1/2 (IDH1/2)-mutant astrocytomas and IDH1/2 wild-type GBM [40].